Gilbert James, Manji Ali
Surgery, Christ Church, University of Oxford, Oxford, GBR.
Medical Sciences, University of Oxford, Oxford, GBR.
Cureus. 2021 Oct 13;13(10):e18744. doi: 10.7759/cureus.18744. eCollection 2021 Oct.
In the wake of highly active antiretroviral therapy (HAART), kidney transplantation has become common practice in HIV-positive recipients. However, management is more complex than that of a seronegative recipient in the pre-operative, peri-operative, and post-operative periods. Although the standard HAART regimen is often modified to improve outcomes and reduce interactions with the post-transplant immunosuppressive regimen, kidney transplantation in HIV-positive individuals is feasible, with high graft survival rates comparable to those in their seronegative counterparts. There is also increasing interest in the possibility of HIV-positive kidney donation, which could increase the donor pool in seropositive patients with end-stage renal disease. This report highlights considerations in the management of a seropositive kidney recipient, reviewing the evidence that underpins current treatment guidelines and highlighting the role of HAART in the dramatic change in attitude towards transplantation in this population. It also addresses studies from multiple countries which have shown favourable outcomes in transplants from HIV-positive donors. This warrants further investigation into seropositive-to-seropositive transplantation as a potential therapeutic option.
在高效抗逆转录病毒疗法(HAART)出现之后,肾移植已成为HIV阳性受者的常见治疗手段。然而,在术前、术中和术后阶段,其管理要比血清学阴性受者更为复杂。尽管通常会对标准的HAART方案进行调整,以改善治疗效果并减少与移植后免疫抑制方案的相互作用,但HIV阳性个体的肾移植是可行的,其移植肾存活率较高,与血清学阴性受者相当。人们对HIV阳性肾脏捐赠的可能性也越来越感兴趣,这可能会增加晚期肾病血清学阳性患者的供体库。本报告重点介绍了血清学阳性肾移植受者管理中的注意事项,回顾了支撑当前治疗指南的证据,并强调了HAART在该人群对移植态度发生巨大转变中所起的作用。报告还探讨了多个国家的研究,这些研究表明HIV阳性供体的移植结果良好。这值得进一步研究血清学阳性到血清学阳性移植作为一种潜在治疗选择的可能性。